Kaiser Permanente Northwest, PA criteria for GLP-1 receptor agonists (reported via primary care PA pathway documentation) Ozempic is FDA-approved for type 2 diabetes glycemic control, cardiovascular risk reduction in T2D patients with known CVD, and CKD progression in T2D patients not for weight loss
otherwise, the management of MDS will be mistakenly guided to focus on glycemic management
For instance, is it your weight
Gradual tapering over 48 weeks significantly reduces this rebound by allowing hunger hormones to normalize progressively rather than spiking suddenly
The development of diabetes mellitus, an additional cardiovascular risk factor, has been strongly associated with psoriasis (99)
Watch the full clip below to see our team in action: Wellness Refined